Trial · NCT04682639
Participant flow30
How many started, completed or left each group, period by period.
1 to 20 of 30
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Double-Blind Treatment Period (24 Weeks) | STARTED | Experimental: Etrasimod 2 mg | 41 | |
| Double-Blind Treatment Period (24 Weeks) | STARTED | Experimental: Etrasimod 1 mg | 39 | |
| Double-Blind Treatment Period (24 Weeks) | STARTED | Placebo Then Etrasimod Any Dose | 28 | |
| Double-Blind Treatment Period (24 Weeks) | STARTED | OLE: Placebo Then Etrasimod 2 mg | 0 | |
| Double-Blind Treatment Period (24 Weeks) | STARTED | OLE: Placebo Then Etrasimod 1 mg | 0 | |
| Double-Blind Treatment Period (24 Weeks) | COMPLETED | Experimental: Etrasimod 2 mg | 30 | |
| Double-Blind Treatment Period (24 Weeks) | COMPLETED | Experimental: Etrasimod 1 mg | 31 | |
| Double-Blind Treatment Period (24 Weeks) | COMPLETED | Placebo Then Etrasimod Any Dose | 24 | |
| Double-Blind Treatment Period (24 Weeks) | COMPLETED | OLE: Placebo Then Etrasimod 2 mg | 0 | |
| Double-Blind Treatment Period (24 Weeks) | COMPLETED | OLE: Placebo Then Etrasimod 1 mg | 0 | |
| Double-Blind Treatment Period (24 Weeks) | NOT COMPLETED | Experimental: Etrasimod 2 mg | 11 | |
| Double-Blind Treatment Period (24 Weeks) | NOT COMPLETED | Experimental: Etrasimod 1 mg | 8 | |
| Double-Blind Treatment Period (24 Weeks) | NOT COMPLETED | Placebo Then Etrasimod Any Dose | 4 | |
| Double-Blind Treatment Period (24 Weeks) | NOT COMPLETED | OLE: Placebo Then Etrasimod 2 mg | 0 | |
| Double-Blind Treatment Period (24 Weeks) | NOT COMPLETED | OLE: Placebo Then Etrasimod 1 mg | 0 | |
| OLE Period (28 Weeks) | STARTED | Experimental: Etrasimod 2 mg | 30 | |
| OLE Period (28 Weeks) | STARTED | Experimental: Etrasimod 1 mg | 31 | |
| OLE Period (28 Weeks) | STARTED | Placebo Then Etrasimod Any Dose | 0 | |
| OLE Period (28 Weeks) | STARTED | OLE: Placebo Then Etrasimod 2 mg | 12 | |
| OLE Period (28 Weeks) | STARTED | OLE: Placebo Then Etrasimod 1 mg | 12 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04682639/flow